Sensorion
ALSEN.PAALSEN.PA · Stock Price
Historical price data
Overview
Sensorion's mission is to address the profound unmet medical need in hearing loss through a three-pillar strategy: Restore hearing via gene therapy for genetic disorders, Treat acute hearing loss with small molecules, and Prevent hearing loss in various settings. The company has established a proprietary R&D platform and advanced its lead gene therapy candidate, OTOF-GT, into a Phase 1/2 trial for otoferlin deficiency. Its strategy combines internal development with strategic partnerships to build a comprehensive portfolio targeting both rare and common forms of auditory impairment.
Technology Platform
An integrated R&D platform combining deep inner ear biology expertise to develop both AAV-based gene therapies for targeted cochlear delivery and small molecules for hair cell and neuron protection/repair.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| SENS-401 + SENS-401 | Severe Sudden Sensorineural Hearing Loss | Phase 2/3 | |
| SENS-401 (R-Azasetron Besylate) | Hearing Loss | Phase 2 | |
| SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet | Acute Unilateral Vestibulopathy (AUV) | Phase 2 | |
| SENS-401 (R-Azasetron Besylate) | Hearing Loss Ototoxic | Phase 2 | |
| SENS-218 | Inner Ear Diseases | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Sensorion is a European pioneer but faces competition from US-based firms like Akouos (Eli Lilly) and Decibel Therapeutics in gene therapy. The small molecule landscape has seen setbacks, but new entrants continue. The company's focused expertise and dual-platform strategy are differentiators, but it competes with entities possessing greater financial resources.